[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_97":98},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","t5cvg888laq6189ozfg7h20wh","revision",2,"title","Aimei Health Technology Co., Ltd 修订 8-K：延期一个月完成业务合并期限","originalTitle","Aimei Health Technology Co., Ltd. (0001979005) (Filer)","summary","Aimei Health Technology Co., Ltd 提交 8-K/A 修订文件，删除原 8-K 中关于 United Hydrogen 的提及；其余信息未作修改。","reason","source",{"_11":87,"_88":89,"_90":91,"_92":57,"_93":94,"_95":96},"links",{"_84":85,"_63":86},"publishedAt","2026-11-03T00:30:14.000Z","discoveredAt","2026-11-03T11:32:43.087Z","timelineAt","category","ai-products","tags",[81,82,83],"stockSymbols",[80],"score",18,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fyroQndtzvXE",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","c96d8d51-744c-4bc9-bcf7-cc4393511729","Aimei Health修订8-K并删除United Hydrogen提及",{"_72":73,"_15":74},"zh","

United\nStates

SECURITIES\nAND EXCHANGE COMMISSION

Washington,\nD.C. 20549

Form\n8-K/A

(Amendment\nNo. 1)

Current\nReport

Pursuant\nto Section 13 or 15(d) of the

Securities\nExchange Act of 1934

October\n5, 2026

Date\nof Report (Date of earliest event reported)

AIMEI\nHEALTH TECHNOLOGY CO., LTD

(Exact\nName of Registrant as Specified in its Charter)

\n \n \n \n \n \n \n \n \n \n \n \n \n

Cayman\n Islands

001-41880

00-0000000 N/A

(State\n or other jurisdiction

of\n incorporation)

(Commission

File\n Number)

(I.R.S.\n Employer

Identification\n No.)

\n \n \n \n \n \n \n \n \n

10\n East 53rd Street, Suite 3001

New\n York, NY

10022

(Address of Principal Executive\n Offices)

(Zip Code)

86-13758131392

Registrant’s\ntelephone number, including area code

N/A

(Former\nname or former address, if changed since last report)

Check\nthe appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under\nany of the following provisions:

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

☐	Written communications\n pursuant to Rule 425 under the Securities Act

☐	Soliciting material pursuant\n to Rule 14a-12 under the Exchange Act

☐	Pre-commencement communications\n pursuant to Rule 14d-2(b) under the Exchange Act

☐	Pre-commencement communications\n pursuant to Rule 13e-4(c) under the Exchange Act

Securities\nregistered pursuant to Section 12(b) of the Act:

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

Title\n of each Class	Trading\n Symbol(s)	Name\n of each exchange on which registered
Ordinary\n Shares, par value $0.0001 per share	AFJK	The Nasdaq Stock Market\n LLC
Rights,\n exchangeable into one-fifth of one Ordinary Share	AFJKR	The Nasdaq Stock Market\n LLC
Units,\n each consisting of one Ordinary Share and one Right	AFJKU	The Nasdaq Stock Market\n LLC

Indicate\nby check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)\nor Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging\ngrowth company ☒

If\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Explanatory\nNote

Aimei\nHealth Technology Co., Ltd is filing this amendment to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission\non October 5, 2026 (the “Original 8-K”) solely to remove the reference in Item 2.03 of the Original 8-K to\nUnited Hydrogen in the description of the Promissory Note (as defined below). Except for the foregoing, this amendment does not amend,\nmodify or update the information contained in the Original 8-K.

Item\n2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

Extension\nof the Termination Date

An\naggregate of $34,330.96 (the “Extension Payment”) has been deposited into the trust account of Aimei Health\nTechnology Co., Ltd (the “Company”) for its public shareholders, representing the lesser of (i) $80,000 for all outstanding\npublic shares and (ii) $0.033 for each outstanding public share for each monthly extension, which enables the Company to further extend\nthe period of time it has to consummate its initial business combination by one month (the “Extension”) from\nOctober 6, 2026 to November 6, 2026 (the “Termination Date”). The Extension is the twenty-third extension permitted\nunder the Amended and Restated Articles of Association of the Company currently in effect.

Promissory\nNote

In\nconnection with the Extension, the Company issued, on October 5, 2026, an unsecured promissory note in the total principal amount of\n$34,330.96 (the “Promissory Note”) to Aimei Investment Ltd, a Cayman Islands exempted company (the “Payee”),\nto fund the Extension Payment. The Promissory Note does not bear interest and the principal thereunder becomes due and payable upon the\ndate on which the Company consummates a business combination (the “Business Combination”). The Payee has the\nright, but not the obligation, to convert the Promissory Note, in whole or in part, into private units of the Company, at a price of\n$10.00 per unit, each consisting of one ordinary share and one right to receive one-fifth (1/5) of one ordinary share of the Company,\nimmediately prior to the consummation of the Business Combination, by providing the Company with written notice of its intention to convert\nthe Promissory Note at least two business days prior to the closing of the Business Combination.

The\nforegoing description of the Promissory Note is not complete and is qualified in its entirety by reference to the text of such document,\nwhich is filed as Exhibit 10.1 hereto and which is incorporated herein by reference.

Item\n9.01 Exhibits.

(d)\nExhibits

\n \n \n \n \n \n \n \n \n \n \n \n \n

Exhibit\n No.		Description
10.1		Promissory Note, dated October 5, 2026
104		Cover Page Interactive\n Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.

Date:\nNovember 2, 2026

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

	Aimei Health Technology Co., Ltd

	By:	/s/ Junheng\n Xie
	Name:	Junheng Xie
	Title:	Chief Executive Officer and Director
		(Principal Executive Officer)

","zhKind","complete","AFJK","公司与财报","融资","Nasdaq","aihot","/items/t5cvg888laq6189ozfg7h20wh","https://www.sec.gov/Archives/edgar/data/1979005/000149315226049665/0001493152-26-049665-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1794873600&sig=187d1741eb567c1f","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1794873600&sig=bf6a936df2e54c4a 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1794873600&sig=732799f81e0d268a 96w","changelogVersion","2026-10-01T08:00"]